Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 211 entries
View as:

Nab-PCE vs PC for MM After Failure of Anti-PD-1

Phase: N/A Priority: Normal
NCT ID: NCT03917069 Org: User:
Start: 03/23/19 End: 09/30/22 Due: 09/30/23

A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04023617 Org: User:
Start: 07/08/19 End: 05/30/21 Due: 05/30/22

PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT05803746 Org: User:
Start: 07/15/22 End: 07/15/24 Due: 07/15/25

[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT04693169 Org: User:
Start: 01/15/21 End: 12/12/24 Due: 12/12/25

Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03051542 Org: User:
Start: 03/01/17 End: 12/31/20 Due: 12/31/21

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06211114 Org: User:
Start: 02/09/24 End: 02/28/27 Due: 02/28/28

Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03051568 Org: User:
Start: 03/01/17 End: 12/31/20 Due: 12/31/21

Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06926179 Org: User:
Start: 12/01/24 End: 03/31/28 Due: 03/31/29

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04764084 Org: User:
Start: 04/01/21 End: 02/28/23 Due: 02/28/24

PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03955354 Org: User:
Start: 03/05/19 End: 04/10/21 Due: 04/10/22

Adaptive Therapy for Resected Stage ⅠB-Ⅱ NSCLC Patients With Undetectable MRD

Phase: N/A Priority: Normal
NCT ID: NCT06924710 Org: User:
Start: 04/15/25 End: 12/31/29 Due: 12/31/30

CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05436093 Org: User:
Start: 06/23/22 End: 12/31/24 Due: 12/31/25

Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)

Phase: N/A Priority: Normal
NCT ID: NCT02179528 Org: User:
Start: 09/30/14 End: 09/30/17 Due: 09/30/18

Quality of Life in Advanced Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04408859 Org: User:
Start: 04/17/18 End: 01/10/22 Due: 01/10/23

Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04629027 Org: User:
Start: 03/03/21 End: 05/30/23 Due: 05/30/24

Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study

Phase: N/A Priority: Normal
NCT ID: NCT04462965 Org: User:
Start: 05/30/20 End: 06/30/25 Due: 06/30/26

Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion

Phase: N/A Priority: Normal
NCT ID: NCT01256801 Org: User:
Start: 11/30/10 End: 12/31/13 Due: 12/31/14

Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase: N/A Priority: Normal
NCT ID: NCT05955209 Org: User:
Start: 08/01/23 End: 08/01/25 Due: 08/01/26

Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Digestive System

Phase: N/A Priority: Normal
NCT ID: NCT02233205 Org: User:
Start: 10/31/14 End: 06/30/16 Due: 06/30/17

Molecular Imaging of Gastric Cancer Metastatic Lymph Nodes with 99mTc-3PRGD2 Probe.

Phase: N/A Priority: Normal
NCT ID: NCT06435741 Org: User:
Start: 06/06/24 End: 12/31/25 Due: 12/31/26

Al18F-HER2-BCH PET in Breast Patients Treated With Neoadjuvant Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06909604 Org: User:
Start: 01/01/25 End: 12/30/26 Due: 12/30/27

A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.

Phase: N/A Priority: Normal
NCT ID: NCT02398552 Org: User:
Start: 03/31/15 End: 03/31/17 Due: 03/31/18

Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT05789043 Org: User:
Start: 03/21/23 End: 02/15/27 Due: 02/15/28

Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04750772 Org: User:
Start: 10/16/19 End: 01/31/23 Due: 01/31/24

To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT05051865 Org: User:
Start: 10/09/21 End: 08/30/24 Due: 08/30/25